BCL6 and angioimmunoblastic T-cell lymphoma: Although BCL6 expression and RHOA G17V mutation were significantly higher in AITL patients than in PTCL-NOS (both p < 0.01), neither definite clinical nor prognostic differences were found among above three groups of PTCLs.